Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | RPA1 | P27694 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6292704 | 0.84 | PDE3B (0.40) | POLB | |
| SCHEMBL6289364 | 0.78 | MAPK14 (0.35) | MAPK14S1PR1S1PR3 | |
| SCHEMBL6289386 | 0.76 | MAPK14 (0.36) | MAPK14MPOCACNA1GCACNA1HCACNA1I | |
| SCHEMBL6292842 | 0.75 | PTGER4 (0.42) | CACNA1GCACNA1HCACNA1ITP53LMNA | |
| SCHEMBL6288889 | 0.72 | MAOB (0.39) | MAPK14MPOCACNA1GCACNA1HCACNA1I | |
| SCHEMBL6289395 | 0.72 | KDM5A (0.40) | MAPK14MPORXRAKDM5AKDM5B | |
| SCHEMBL6698891 | 0.71 | PTGS1 (0.41) | CACNA1GCACNA1HCACNA1IPTGS1PTGS2 | |
| SCHEMBL6476888 | 0.71 | RXRA (0.35) | TP53RXRAKDM5AKDM5BP2RY14 | |
| SCHEMBL6292735 | 0.70 | MMP13 (0.35) | MAPK14MPOS1PR1S1PR3 | |
| SCHEMBL6292190 | 0.69 | MAPT (0.45) | CACNA1GCACNA1HCACNA1IS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949651-B2 | Fused bicyclic metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | LINCOLN FOODSERVICE PRODUCTS INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2004014375-A2 | FUSED BICYCLIC METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034054-A1 | Fused bicyclic metalloproteinase inhibitors | MMP9, MMP1, MMP2 | MAPK14 3042/4885MPO 70/4885CACNA1G 3523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.